Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
DYNASTY-Breast02
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
- NCT06018337 ↗
- Active, not recruiting
- DualityBio Inc.
- Standard
We haven't built an HCP commentary report on DYNASTY-Breast02 (DB-1303/BNT323, capecitabine and 2 more in Metastatic Breast Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on DYNASTY-Breast02 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 10 | |
| YouTube | 2 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Multi-center, Open-Label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Metastatic Breast Cancer
- Interventions
- DB-1303/BNT323; Capecitabine; Paclitaxel; Nab-paclitaxel
- Arms
- DB-1303/BNT323 · Experimental
- investigator's choice single agent chemotherapy · Active comparator
- Enrollment
- 541
- Primary outcomes
- Progression-free survival (PFS) in the HR+, HER2-low population
- Sponsor
- DualityBio Inc. with BioNTech SE
- Start
- Jan 18, 2024
- Primary completion
- Aug 12, 2026
- Results posted
- No
- Registry record
- NCT06018337 · updated Sep 24, 2026